Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Shares Outstanding (Weighted Average): 2014-2024

Historic Shares Outstanding (Weighted Average) for Coherus Oncology (CHRS) over the last 11 years, with Dec 2024 value amounting to $115.9 million.

  • Coherus Oncology's Shares Outstanding (Weighted Average) rose 0.88% to $116.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $116.2 million, marking a year-over-year increase of 0.88%. This contributed to the annual value of $115.9 million for FY2024, which is 4.07% up from last year.
  • According to the latest figures from FY2024, Coherus Oncology's Shares Outstanding (Weighted Average) is $115.9 million, which was up 4.07% from $111.4 million recorded in FY2023.
  • Coherus Oncology's 5-year Shares Outstanding (Weighted Average) high stood at $115.9 million for FY2024, and its period low was $72.8 million during FY2020.
  • Moreover, its 3-year median value for Shares Outstanding (Weighted Average) was $111.4 million (2023), whereas its average is $101.7 million.
  • Data for Coherus Oncology's Shares Outstanding (Weighted Average) shows a peak YoY surged of 43.18% (in 2023) over the last 5 years.
  • Over the past 5 years, Coherus Oncology's Shares Outstanding (Weighted Average) (Yearly) stood at $72.8 million in 2020, then grew by 5.48% to $76.8 million in 2021, then rose by 1.29% to $77.8 million in 2022, then spiked by 43.18% to $111.4 million in 2023, then rose by 4.07% to $115.9 million in 2024.